Clinical evidence for effectiveness of PhenCal(TM) in maintaining weight loss in an open-label, controlled, 2-year study

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 10, 1997, Pages 745-763

  Blum, Kenneth ^a,b,k   Cull, John G ^c   Chen, Thomas J H ^d   Garcia Swan, Susan ^e   Holder, Jay M ^b,c,f   Wood, Robert ^g   Braverman, Eric R ^b,h   Bucci, Luke R ⁱ   Trachtenberg, Michael C ^j  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b Amer Coll Addicitionology C   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^e Behav Medicine Medical Group Clinic   (United States)

^f UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Weider Nutrition Group   (United States)

^j Southwest Information Resources   (United States)

^k NONE   (United States)

more..

Author keywords

Carbohydrate bingeing; Maintaining weight loss; Nutritional supplement; Obesity; PhenCal(TM)

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMINO ACID; CARNITINE; CENTRUM; CHROMIUM PICOLINATE; GLUTAMINE; PHENCAL; PHENYLALANINE; PYRIDOXAL 5 PHOSPHATE; TRYPTOPHAN; UNCLASSIFIED DRUG; VITAMIN;

ADULT; ARTICLE; BULIMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG CAPSULE; FAMILY HISTORY; FEMALE; FOOD PREFERENCE; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; MULTIPLE REGRESSION; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0030703544     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80108-7     Document Type: Article

References (70)

1. Lockwood DH, Amatruda JM. Very low calorie diets in the management of obesity. Annu Rev Med. 1984;5:373-381.
2. Krueger DW. Eating disorders. In: Lowenson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance Abuse: A Comprehensive Textbook. 2nd ed. Baltimore: Williams & Wilkins; 1992:371-379.
3. Weintraub M, Bray GA. Drug treatment of obesity. Med Clin North Am. 1989;73:237-249.
4. Bouchard C. Genetics in obesity. Med Clin North Am. 1989;73:67-81.
5. Stunkard AJ, Harris JR, Pedersen NL, et al. The body mass index of twins who have been reared apart. NEJM. 1990;322:1483-1487.
6. 2 Dopamine receptor gene and obesity. Int J Eating Disord. 1994;15:205-217.
7. 2) as a major gene in obesity and height. Biochem Med Metab Biol. 1993;50:176-185.
8. 2) in obesity with comorbid substance use disorder: A preliminary report. Pharmacogenetics. 1995;6:297-305.
9. 1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch Gen Psychiatry. 1992;49:723-727.
10. 2 receptor gene. Mol Psychiatry. 1996;1:325-335.
11. 2 receptor gene variants: Association and linkage studies in impulsive-addictive-compulsive behavior. Pharmacogenetics. 1995;6:199-204.
12. 2, DβH, and DAT1. Am J Med Genet. 1996;67:264-288.
13. Cook EH, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 1995;56:993-998.
14. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-432.
15. Peileymounter MA, Cullen MJ, Baker MB, et al. Effect of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:546-549.
16. Bray GA. Nutrient balance: New insights into obesity. Int J Obes. 1987;11:83-95.
17. Blum K, Cull JG, Braverman ER, Comings DE. Reward deficiency syndrome. Am Sci. 1996;84:132-145.
18. Blum K, Kozlowski G. Ethanol and neuromodulator interactions: A cascade model of reward. In: Oliat H, Parvez S, Parvez H, eds. Progress in Alcohol Research. Vol. 2. Alcohol and Behavior: Basic and Scientific Aspects. Amsterdam: VNU Science Press; 1990: 131-147.
19. Blum K, Cull JG, Braverman ER, et al. Reward deficiency syndrome: Neurobiological and genetic aspects. In: Blum K, Noble EP, eds. Handbook of Psychiatric Genetics. Boca Raton, Fla: CRC Press; 1997:311-327.
20. Leibowitz SF. Brain neurotransmitters and appetite regulation. Psychopharmacol Bull. 1985;21:412-418.
21. Leibowitz SF, Hor L. Endorphinergic and noradrenergic systems in the paraventricular nucleus: Effects on eating behavior. Peptides. 1982;3:421-428.
22. Kaye WH, Jimerson DC, Lake CR, et al. Altered norepinephrine metabolism following long-term recovery in patients with anorexia nervosa. Psychiatry Res. 1985;14:333-342.
23. Kaye WH, Ebert MH, Gwirtsman HE, et al. Differences in brain serotonergic metabolism between non-bulimic and bulimic patients with anorexia nervosa. Am J Psychiatry. 1984; 141:1598-1601.
24. Cooper SJ, Jackson A, Kirkham TC, et al. Endorphins, opiates and food intake. In: Rodgers RJ, Cooper SJ, eds. Endorphins, Opiates and Behavioral Processes. New York: John Wiley and Sons; 1988:143-186.
25. Gosnell BA. Central structures involved in opioid-induced feeding. Fed Proc. 1987;46: 163-167.
26. Bouchard C. Genetics of obesity: An update on molecular markers. In: Bouchard C, ed. The Genetics of Obesity. Boca Raton, Fla: CRC Press; 1994:810-813.
27. Blum K, Trachtenberg MC, Elliott CE, et al. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and poly-drug abusers. Double-blind placebo-controlled study of the nutritional adjunct SAAVE. Alcohol. 1988; 5:481-493.
28. Blum K, Allison D, Trachtenberg MC, et al. Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30-day inpatient treatment program by the neuronutrient Tropamine. Curr Ther Res. 1988;43:1204-1214.
29. Brown RJ, Blum K, Trachtenberg MC. Neurodynamics of relapse prevention: A neuronutrient approach to outpatient DUI offenders. J Psychoact Drugs. 1990;22:173-187.
30. Blum K, Trachtenberg MC, Cook DW. Neuronutrient effects on weight loss in carbohydrate bingers: An open clinical trial. Curr Ther Res. 1990;48:217-233.
31. Morley JE, Levine AS. Corticotropin releasing factor, grooming and ingestive behavior. Life Sci. 1988;31:1459-1464.
32. Moore R, Mills IH, Forster A. Naloxone in the treatment of anorexia nervosa: Effect on weight gain and lipolysis. JR Soc Med. 1982;74:129-131.
33. Morley JE, Parker S, Levine AS. Effect of butorphanol tartrate on food and water consumption in humans. Am J Clin Nutr. 1985;42:1175-1178.
34. Riviere PJM, Bueno L. Origin of the stimulation of food intake by oral administration of enkephalinase inhibitors in sheep. Life Sci. 1987;41:333-339.
35. Blum K, with Payne JE. Alcohol and the Addictive Brain. New York: The Free Press (Simon and Schuster); 1991.
36. Blum K, Briggs AH, Trachtenberg MC. Ethanol ingestive behavior as a function of central neurotransmission. Experientia. 1989;45:444-452.
37. Blum K. A commentary on neurotransmission restoration as a common mode of treatment for alcohol, cocaine, and opiate abuse. Integr Psychiatry. 1989;6:199-204.
38. Stein L, Beluzzi JD. Brain endorphins and the sense of well-being: A psychobiological hypothesis. Adv Biochem Psychopharmacol. 1978;18:299-311.
39. Heidbreder C, Roques B, Vanderhaeghen JJ, et al. Kelatorphan, a potent enkephalinase inhibitor, presents opposite properties when injected intracerebroventricularly or into the nucleus accumbens on intracranial self-stimulation. Neurochem Int. 1988;12:347-350.
40. Chesselet MF, Cheramy A, Reisine TD, et al. Morphine and delta-opiate agonists locally stimulate in vivo dopamine release in CA1 caudate nuclei. Nature. 1981;291:320-322.
41. Koob GF. Drug abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13:177-184.
42. Blum K, Briggs AH, Trachtenberg MC, et al. Enkephalinase inhibition: Regulation of ethanol intake in genetically predisposed mice. Alcohol. 1986;4:449-456.
43. Frohman LA. CNS peptides and glucoregulation. Annu Rev Physiol. 1983;45:95-107.
44. Fullerton DT, Getto CJ, Swift WJ, et al. Sugar, opioids, and binge eating. Brain Res Bull. 1985;14:673-680.
45. Matsumura M, Fukushima T, Saito H, et al. In vivo and in vitro effects of beta-endorphin on glucose metabolism in the rat. Horm Metab Res. 1984;16:27-31.
46. Oltmans GA. Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res. 1983;273:369-373.
47. Blum K, Trachtenberg M, Ramsey J. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: A pilot study. Int. J Addict. 1988;23:991-998.
48. Blum K, Trachtenberg MC. Neurogenetic deficits caused by alcoholism: Restoration by SAAVE, a neuronutrient intervention adjunct. J Psychoact Drugs. 1988;20:297-313.
49. DeFrance JJ, Hymel C, Trachtenberg MC, et al. Enhancement of attention processing by KANTROL in healthy humans: A pilot study. Clin Electroencephalogr. 1997;28:68-75.
50. Cold JA. NeuRecover-SA in the treatment of cocaine withdrawal and craving: A pilot study. Clin Drug Invest. 1996;12:1-7.
51. Weintraub M, Sundaresan P, Madan M, et al. Long term weight control study (weeks 0 to 34). Clin Pharmacol Ther. 1992;51:586-594.
52. Grand-Guy B, Apelbaum M, Crepaldi G. International trial of long-term d-fenfluramine in obesity. Lancet. 1989;11:1142-1144.
53. Levitsky DA, Troiano R. Metabolic consequences of fenfluramine for the control of body weight. Am J Clin Nutr. 1992;55(Suppl):167S-172S.
54. Turner P. Benefit:risk consideration in long-term therapy with dexfenfluramine. Int J Obesity Related Metabol Disorders. 1992;3:S15-S17.
55. Wurtman RJ, Fernstrom JD. Control of brain monoamine synthesis by diet and plasma amino-acids. Am J Clin Nutr. 1975;28:638-647.
56. Wurtman RJ. Nutrients that modify brain function. Sci Am. 1982;246:50-59.
57. Ehrenpreis S, Balagot RC, Comaty JE, Myles SB. Naloxone reversal analgesia in mice produced by D-phenylalanine and hydrocinamic acid, inhibitors of carboxypeptidase A. In: Bonica JJ, Ventafridda V, eds. Advances in Pain Research Therapy. New York: Raven Press; 1979:479-488.
58. Atkinson RL. Opioid regulation of food intake and body weight in humans. Fed Proc. 1987;46:178-182.
59. Bakshi VP, Kelly AE. Striatal regulation of morphine-induced hyperphagia: An anatomical mapping study. Psychopharmacology. 1993;111:207-214.
60. Gosnell BA, Levine AS, Morley JE. The stimulation of food intake by selective agonists of mu, kappa and delta opioid receptors. Life Sci. 1986;38:1081-1088.
61. Drewnowski A, Krahn DD, Demitrack MA, et al. Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr. 1995;6:1206-1212.
62. Shimomura Y, Oku J, Glick Z, Bray GA. Opiate receptors, food intake and obesity. Physiol Behav. 1982;28:441-445.
63. Shor-Posner G, Azar PA, Filart R, et al. Morphine-stimulated feeding analysis of macronutrient selection and paraventricular nucleus lesions. Pharmacol Biochem Behav. 1986; 24:931-939.
64. Jonas JM, Gold MS. The use of opiate antagonists in treating bulimia: A study of low-dose versus high-dose naltrexone. Psychiatry Res. 1987;24:195-199.
65. Broekkamp CLE, Phillips AG, Cools R. Stimulant effect of enkephalin microinjection into the dopaminergic A10 area. Nature. 1979;278:560-562.
66. Gilman MA, Lichtigfeld FJ. The opioids, dopamine, cholecystokinin, and eating disorders. Clin Neuropharmacol. 1986;9:91-97.
67. Routtenberg A, Santos-Anderson R. The role of prefrontal cortex in intracranial self-stimulation: A case history of anatomical localization of motivational substrates. In: Iversen LF, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology. New York: Plenum Press; 1977:1-53.
68. Hoebel BG. The Psychopharmacology of feeding. In: Iversen LF, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology. New York: Plenum Press; 1977:55-129.
69. Gardner EL. Brain reward mechanisms. In: Lowenson JH, Ruiz P, Millman RB, Landgrod JG, eds. Substance Abuse: A Comprehensive Textbook. 3rd ed. Baltimore: Williams & Wilkins; 1997:51-85.
70. Gardner EL. Neurobiology and genetics of addiction: Implications of "Reward Deficiency Syndrome" for therapeutic strategies in chemical dependency. In: Elston J, ed. Addiction Conferences: Russell Sage Conference on Addictions. New York: Wiley & Sons. In press.